Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

VPA-985 characterized as potent, selective, orally active V2 antagonist

Nov. 13, 1998

BG-9719 has potent natriuretic effects in patients with CHF

Nov. 13, 1998

McMaster University researchers target potential gene therapies for arthritis

Nov. 13, 1998

Bristol-Myers Squibb initiates phase III HBV clinical trials; phase II data reported

Nov. 13, 1998

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Nov. 13, 1998

Leflunomide reduces symptoms of rheumatoid arthritis, slows disease progression in new studies

Nov. 13, 1998

First clinical results reported for novel gene therapy in coronary artery disease

Nov. 12, 1998

SPBN: a free radical scavenger with potential in pediatric head trauma

Nov. 12, 1998

NK2 antagonist from Zeneca blocks increased pulmonary resistance in guinea pigs

Nov. 12, 1998

New mechanism of action described for immunomodulating agent OM-89

Nov. 12, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...